Article

Screening of genetic and expression alterations of SRC1 gene in prostate cancer

The Prostate (impact factor: 3.48). 09/2006; 66(13):1391 - 1398. DOI:10.1002/pros.20427 pp.1391 - 1398

ABSTRACT BACKGROUND
Genetic alterations of the SRC1 gene have not been thoroughly studied in prostate cancer.MATERIALS AND METHODS
Five prostate cancer cell lines and 32 xenografts were screened for mutations and gene copy number alterations. Subsequently, frequencies of detected sequence variations were further analyzed in 44 clinical prostate cancers, 6 benign prostate hyperplasias, and 48 normal controls. Finally, the protein expression of SRC1 in 254 clinical prostate tumors was investigated.RESULTSThree non-recurrent sequence variations, and one single nucleotide polymorphism in the coding region of SRC1, as well as one case of SRC1 gene amplification were found. The protein expression of SRC1 was higher in androgen ablation resistant than untreated prostate carcinomas, but the difference was not statistically significant (P = 0.0796).CONCLUSIONS
Genetic alterations of SRC1 are rare in prostate cancer. The nuclear protein accumulation of SRC1 seems to be mildly increased in androgen ablation resistant prostate cancers. Prostate 66: 1391–1398, 2006. © 2006 Wiley-Liss, Inc.

0 0
 · 
0 Bookmarks
 · 
14 Views
  • Source
    Article: Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
    H E Mäki, O R Saramäki, L Shatkina, P M Martikainen, T L J Tammela, W M van Weerden, R L Vessella, A C B Cato, T Visakorpi
    [show abstract] [hide abstract]
    ABSTRACT: BAG-1L (Bcl-2-associated anthanogene 1) has been found to interact with androgen receptor (AR), and has been suggested to be involved in the development of prostate cancer. In order to determine the presence of genetic and/or expression alterations of BAG-1L in prostate cancer, we analysed human prostate cancer cell lines and xenografts as well as patient samples of untreated, hormone-naïve, and hormone-refractory prostate carcinomas for sequence variations using denaturing high-performance liquid chromatography (DHPLC), for gene copy number using fluorescence in situ hybridization (FISH), and for expression using both quantitative RT-PCR and immunostaining. Only one sequence variation was found in all 37 cell lines and xenografts analysed. BAG-1 gene amplification was detected in two xenografts. In addition, gene amplification was found in 6 of 81 (7.4%) hormone-refractory clinical tumours, whereas no amplification was found in any of the 130 untreated tumours analysed. Additionally, gain of the BAG-1 gene was observed in 27.2% of the hormone-refractory tumours and in 18.5% of the untreated carcinomas. In a set of 263 patient samples, BAG-1L protein expression was significantly higher in hormone-refractory tumours than in primary tumours (p = 0.002). Altogether, these data suggest that amplification and overexpression of BAG-1L may be involved in the progression of prostate cancer.
    The Journal of Pathology 09/2007; 212(4):395-401. · 6.32 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

254 clinical prostate tumors
 
32 xenografts
 
44 clinical prostate cancers
 
6 benign prostate hyperplasias
 
androgen ablation resistant
 
androgen ablation resistant prostate cancers
 
gene copy number alterations
 
mutations
 
nuclear protein accumulation
 
Prostate 66
 
prostate cancer
 
prostate cancer cell lines
 
prostate cancer.MATERIALS
 
single nucleotide polymorphism
 
SRC1
 
SRC1 gene
 
SRC1 gene amplification
 
untreated prostate carcinomas
 

Hanna E Mäki